Visión actual de la terapia con células CAR-T

Autores/as

  • Carmen Burgaleta Alonso de Ozalla Hospital Universitario Príncipe de AsturiasUniversidad de Alcalá

DOI:

https://doi.org/10.37536/RIECS.2022.7.1.312

Palabras clave:

Terapia CAR, Receptor antígeno quimérico, Síndrome liberación citoquinas

Resumen

La terapia con células T portadoras de antígeno quimérico (CAR), es una forma de inmunoterapia adoptiva para neoplasias. Los resultados obtenidos con formas refractarias de Leucemia Aguda Linfoblástica (LLA) y Linfoma no Hodgkin han permitido confirmar esta modalidad terapéutica en neoplasias hematológicas mediante CAR dirigidas al CD19 y se prevé la ampliación de su uso tanto en onco-hematología como en tumores sólidos con el desarrollo de nuevos CAR. Las limitaciones del tratamiento son la toxicidad asociada a un síndrome de liberación de citoquinas y neurotoxicidad y la limitación de la duración de la respuesta. En la actualidad se está a la búsqueda de estrategias que mejoren los resultados actuales, disminuyendo las complicaciones y prolongando la duración de SLE.

Citas

Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90:720–4.

Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013;10:267–76.

Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388–98.

June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64–73.

Rouce RH, Sharma S, Huynh M, Heslop HE. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol 2017;176:688–704.

Schuster, S.J.; Svoboda, J.; Chong, E.A.; Nasta, S.D.; Mato, A.R.; Anak, Ö.; Brogdon, J.L.; Pruteanu-Malinici, I.; Bhoj, V.; Landsburg, D.; et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N. Engl. J. Med. 2017, 377, 2545–2554.

Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531- 2544.

FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. https:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. United States Food and Drug Administration Press ReleaseAugust 30, 2017. [39].

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma: Yescarta is the second gene therapy product approved in the U.S https://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm. United States Food and Drug Administration Press Release October 18, 2017.

FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm. United States Food and Drug Administration Press ReleaseMay 1, 2018.19. van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. The Lancet Haematology. 2021 Jun;8(6):e446–61

Jennifer N. Brudno and James N. Kochenderfe. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood review. 2019 March ; 34: 45–55.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.

Frey N. Cytokine Release Syndrome: Who is at Risk and How to Treat. Best Pract Res Clin Haematol (2017) 30(4):336–40.

Moreno-Cortes, E.; Forero-Forero, J.V.; Lengerke-Diaz, P.A.; Castro, J.E. Chimeric Antigen Receptor T Cell Therapy in Oncology -Pipeline at a Glance: Analysis of the ClinicalTrials.gov Database. Crit. Rev. Oncol. Haematol. 2021, 159, 103239.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439–48.

Nastoupil, L.J.; Jain, M.D.; Spiegel, J.Y.; Ghobadi, A.; Lin, Y.; Dahiya, S.; Lunning, M.A.; Lekakis, L.J.; Reagan, P.M.; Oluwole, O.O.; et al. Axicabtagene Ciloleucel (Axi-Cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood 2018, 132 (Suppl. 1)

Pasquini, M.C.; Locke, F.L.; Herrera, A.F.; Siddiqi, T.; Ghobadi, A.; Komanduri, K.V.; Hu, Z.-H.; Dong, H.; Hematti, P.; Nikiforow, S.; et al. Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood 2019, 134 (Suppl. 1)

Mian, A.; Wei, W.; Winter, A.M.; Khouri, J.; Jagadeesh, D.; Anwer, F.; Gerds, A.T.; Dean, R.M.; Sobecks, R.; Pohlman, B.; et al. Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Results from an Intention-to-Treat Analysis. Leuk. Lymphoma 2021, 62, 1344–1352

van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell Therapy for multiple mieloma: states of art and prospects. The lancet Haematology. 2021. 8; 6: 446-61

D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020 Jan;34(1):21–34. nd Kochenderfer Page 21

Langebrake, C.; Admiraal, R.; van Maarseveen, E.; Bonnin, A.; Bauters, T.; EBMT Working Group. Consensus Recommendations for the Role and Competencies of the EBMT Clinical Pharmacist and Clinical Pharmacologist Involved in Hematopoietic Stem Cell Transplantation. Bone Marrow Transpl. 2020, 55, 62–69.

Yakoub-Agha, I.; Chabannon, C.; Bader, P.; Basak, G.W.; Bonig, H.; Ciceri, F.; Corbacioglu, S.; Duarte, R.F.; Einsele, H.; Hudecek, M.; et al. Management of Adults and Children Undergoing Chimeric Antigen Receptor T-Cell Therapy: Best Practice Recomendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2020, 105, 297–316.

Marzal-Alfaro, M.B.; Escudero-Vilaplana, V.; Revuelta-Herrero, J.L.; Collado-Borrell, R.; Herranz-Alonso, A.; Sanjurjo-Saez, M. Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool from a Multidisciplinary Team Perspective. Front. Oncol. 2021, 11, 636068.

Jain, M.D.; Chavez, J.C.; Shah, B.D.; Khimani, F.; Lazaryan, A.; Davila, M.L.; Liu, H.D.; Falchook, A.D.; Robinson, T.; Kim, S.; et al. Radiation Therapy as a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood 2018, 132, 4220.

Mian, A.; Wei, W.; Winter, A.M.; Khouri, J.; Jagadeesh, D.; Anwer, F.; Gerds, A.T.; Dean, R.M.; Sobecks, R.; Pohlman, B.; et al. Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis. Blood 2019, 134 (Suppl. 1)

Lin, Y.; Neelapu, S.S.; Locke, F.L.; Miklos, D.B.; Vose, J.M.; Rapoport, A.P.; Munoz, J.; Andreadis, C.; Vu, K.; Hill, B.T.; et al. Experience with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. Blood 2019, 134 (Suppl. 1)

Jacobson, C.A.; Hunter, B.; Armand, P.; Kamihara, Y.; Ritz, J.; Rodig, S.J.; Wright, K.; Lipschitz, M.; Redd, R.A.; Maus, M.V.; et al. Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. Blood 2018, 132 (Suppl. 1)

Pinnix, C.C.; Gunther, J.R.; Dabaja, B.S.; Strati, P.; Fang, P.; Hawkins, M.C.; Adkins, S.; Westin, J.; Ahmed, S.; Fayad, L.; et al. Bridging Therapy Prior to Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma. Blood Adv. 2020, 4, 2871–2883.

Nastoupil, L.J.; Jain, M.D.; Feng, L.; Spiegel, J.Y.; Ghobadi, A.; Lin, Y.; Dahiya, S.; Lunning, M.; Lekakis, L.; Reagan, P.; et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 2020, 38, 3119–3128.

Jaglowski, S.; Hu, Z.-H.; Zhang, Y.; Kamdar, M.; Ghosh, M.; Lulla, P.; Sasine, J.; Perales, M.; Hematti, P.; Nikiforow, S.; et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood 2019, 134, 766.

Iacoboni, G.; Villacampa, G.; Martinez-Cibrian, N.; Bailén, R.; Lopez Corral, L.; Sanchez, J.M.; Guerreiro, M.; Caballero, A.C.; Mussetti, A.; Sancho, J.M.; et al. Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. Cancer Med. 2021, 10, 3214–3223.

Locke, F.L.; Ghobadi, A.; Jacobson, C.A.; Miklos, D.B.; Lekakis, L.J.; Oluwole, O.O.; Lin, Y.; Braunschweig, I.; Hill, B.T.; Timmerman, J.M.; et al. Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, phase 1–2 Trial. Lancet Oncol. 2019, 20, 31–42.

Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 2018, 378, 439–448.

Pasquini, M.C.; Hu, Z.H.; Curran, K.; Laetsch, T.; Locke, F.; Rouce, R.; Pulsipher, M.A.; Phillips, C.L.; Keating, A.; Frigault, M.J.; et al. Real-World Evidence of Tisagenlecleucel for Pediatric Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. Blood Adv. 2020, 4, 5414–5424.

Maude, S.L.; Teachey, D.T.; Porter, D.L.; Grupp, S.A. CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia. Blood 2015, 125, 4017–4023.

Yuki Fujiwara, Toshiki Kato, Futoshi Hasegawa, Muha Sunahara and Yoshie Tsurumaki.The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. Review. Pharmaceuticals 2022, 15, 207

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127: 3321–30.

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome. Blood. 2014; 124:188–95.

Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade is a predictive marker for infections in relapsed or refractory B-cell all patients treated with CAR T cells. Clin Infect Dis. 2018; 67:533–40

Gardner R Decreased rates of severe CRS seen with early intervention strategies for CD19 CART cell toxicity management. Blood 2016;128 :586.

Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity Associated With CD19-targeted CAR-T Cell Therapies. CNS Drugs 2018; 32 :1091–101.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist Aug 2018;23 :943–7

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncol. 2018; 23 :943.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and Toxicity Management of 19-28z Car T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Trans Med. 2014; 6: 224-25.

Rice J, Nagel S, Randall J, Hinson HE. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Curr Treat Options Neurol. 2019; 21:40.

Brudno JN, Kochenderfer JN. Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management. Blood Rev. 2019; 34:45–55.

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Resist Tumor-Mediated Inhibition. J. Clin. Invest. 2016; 126 :3130–44.

Zheng W, Carol E, Alli R, Basham JH, Abdelsamed HA, Palmer LE, et al. PI3K Orchestration of the In Vivo Persistence of Chimeric Antigen Receptor-Modified T Cells. Leukemia. 2018. 32:1157–67.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-Targeted CAR T Cells Induce Remission in B-ALL That is Naive or Resistant to CD19-targeted CAR Immunotherapy. Nat Med 2018; 24: 20

Faroogh Marofi, 1 , 2 Heshu Sulaiman Rahman, 3 , 4 Muhammad Harun Achmad, 5 Klunko Nataliya Sergeevna, 6 , 7 Wanich Suksatan et all, A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Front Immunol. 2021; 12: 681984.

Publicado

30-05-2022

Número

Sección

Artículos de Revisión